Session X: “Ongoing CTO Trials” DCB vs. DES in CTO A. Nap, Netherlands
0 likes32 views
The document discusses the CO-CTO trial (NCT04881812), which compares drug-coated balloon (DCB) angioplasty with traditional stenting for treating conditions adjacent to chronic total occlusions. It cites various studies evaluating the effectiveness and situations in which DCBs are beneficial, alongside considerations of patient outcomes such as major adverse cardiac events (MACE) and re-occlusion rates. Overall, the findings suggest specific scenarios where DCBs may offer advantages in managing coronary artery disease.
1 of 12
Download to read offline
More Related Content
Similar to Session X: “Ongoing CTO Trials” DCB vs. DES in CTO A. Nap, Netherlands (20)
Ad
More from Euro CTO Club (20)
Ad
Session X: “Ongoing CTO Trials” DCB vs. DES in CTO A. Nap, Netherlands
- 1. Drug-Coated Balloon Coronary Angioplasty Versus Stenting for Treatment of Disease Adjacent to a Chronic Total Occlusion. Co-CTO Trial NCT04881812 Alexander Nap Amsterdam UMC Netherlands
- 2. I, Alexander Nap DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation Disclosure Statement of Financial Interest
- 3. SIZEDOES MATTER! Claessen et al. JACC Interv 2011 MACE length diameter
- 5. WHY USE DCB? BASKET-2-SMALL DEBUT Rissanen et al. Lancet 2019, Jeger et al. Lancet 2018 minimize DES burden (MACE, PHYSIOLOGY, CABG)
- 6. WHEN USE DCB? Jeger et al. JACC Interv 2020
- 7. WHEN USE DCB? Shin et al. JACC Interv 2023
- 8. WHEN USE DCB? Shin et al. JACC Interv 2023
- 10. DCB IN CTO? Walsh et al. JACC Interv 2020
- 11. Co-CTO - NCT04881812 pPCI DIAMETER STENOSIS (GAIN) 1 Y DIAMETER STENOSIS LATE LUMINAL LOSS RE-OCCLUSION MACE
- 12. DCB CTO ONLY? Terashita et al. Cath Cardiovasc Interv 2023